| Literature DB >> 35401434 |
Carolina Cason1, Giulia Zamagni2, Giorgio Cozzi3, Davide Tonegutto3, Luca Ronfani2, Chiara Oretti4, Andrea De Manzini4, Egidio Barbi3,5, Manola Comar1,5, Alessandro Amaddeo3.
Abstract
The social distancing measures adopted during the coronavirus disease 2019 (COVID-19) pandemic led to a profound change in the behavioral habits of the population. This study analyzes the impact of restriction measures on the shaping of the epidemiology of common winter respiratory pathogens in the pediatric population of northeast of Italy. From August 2020 to March 2021, a total of 1,227 nasopharyngeal swabs from symptomatic pediatric patients were tested for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A and B, adenovirus, other coronaviruses, parainfluenza virus 1-4, enterovirus, bocavirus, metapneumovirus, respiratory syncytial virus, rhinovirus, Bordetella pertussis, Bordetella parapertussis, and Mycoplasma pneumoniae. To relate virus positivity with the clinic characteristics of the subjects enrolled, multinomial logistic models were estimated. SARS-CoV-2 was detected in 5.2% of the children; fever resulted as risk factor for infection [relative risk ratio (RRR) = 2.88, p = 0.034]. Rhinovirus was detected in the 40.7% of the subjects, with cough and rhinitis as risk factors (respectively, RRR = 1.79, p = 0.001 and RRR = 1.53, p = 0.018). Other coronaviruses were found in 10.8% of children and were associated to pharyngodynia (RRR = 4.94, p < 0.001). Adenovirus, observed in 11.6% of subjects, showed to have fever as risk factor (RRR = 6.44, p < 0.001). Bocavirus was detected in 3.2% of children. In conclusion, our results showed that social isolation measures had an impact on the circulation of RSV and influenza, although children under the age of 2 were most affected by the other respiratory infections. Therefore, this study highlights the need for continuing surveillance for a delayed spread of RSV and other respiratory pathogens.Entities:
Keywords: SARS-CoV-2; children; coinfections; epidemiology; respiratory tract infections
Year: 2022 PMID: 35401434 PMCID: PMC8988150 DOI: 10.3389/fmicb.2022.804700
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Characteristics of children enrolled in the study.
| Total | |
|
|
|
| Age (years) | |
| <2 | 299 (24.4) |
| 2–5 | 462 (37.6) |
| 6–9 | 201 (16.4) |
| 10–17 | 265 (21.6) |
|
| |
| Male | 670 (54.6) |
| Female | 557 (45.4) |
|
| |
| PER | 666 (54.3) |
| GP | 536 (43.7) |
| Other | 25 (2.0) |
|
| |
| No | 1,176 (95.8) |
| Yes | 51 (4.2) |
PER, pediatric emergency room; GP, general practitioner.
Number of positive subjects for each pathogen researched.
| Results of analyses | |
| Negative | 465 (37.9) |
| Positive | 762 (61.1) |
|
| |
| SARS-CoV-2 | 64 (5.2) |
| HRV | 499 (40.7) |
| Adenovirus | 142 (11.6) |
| Other coronaviruses | 133 (10.8) |
| Bocavirus | 39 (3.2) |
|
| 4 (0.3) |
| HPIV | 3 (0.2) |
|
| 2 (0.2) |
| Enterovirus | 2 (0.2) |
| Metapneumovirus | 2 (0.2) |
| RSV | 1 (0.1) |
| Influenza virus | 0 (0%) |
|
| 0 (0%) |
HRV, human rhinovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus.
Descriptive statistic by age group.
| Age (years) | |||||
| <2 | 2–5 | 6–9 | 10–17 | ||
|
|
| ||||
| PER | 78 (26.1) | 203 (44.0) | 108 (53.7) | 147 (55.5) | |
| GP | 216 (72.2) | 251 (54.3) | 88 (43.8) | 111 (41.9) | |
| Other | 5 (1.7) | 8 (1.7) | 5 (2.5) | 7 (2.6) | |
|
| 0.379 | ||||
| No | 287 (96.0) | 445 (96.3) | 195 (97.0) | 249 (94.0) | |
| Yes | 12 (4.0) | 17 (3.7) | 6 (3.0) | 16 (6.0) | |
|
|
| ||||
| Negative | 93 (31.1) | 143 (30.9) | 89 (44.3) | 140 (52.8) | |
| Positive for some infection | 206 (68.9) | 319 (69.1) | 112 (55.7) | 125 (47.2) | |
|
| |||||
| SARS-CoV-2 | 25 (8.4) | 14 (3.0) | 10 (5.0) | 15 (5.7) |
|
| Other coronaviruses | 44 (14.7) | 66 (14.3) | 16 (8.0) | 7 (2.6) |
|
| HRV | 105 (35.1) | 207 (44.8) | 84 (42.8) | 103 (38.9) | 0.056 |
| Adenovirus | 63 (21.1) | 68 (14.7) | 6 (3.0) | 5 (1.9) |
|
| Bocavirus | 5 (1.7) | 30 (6.5) | 4 (2.0) | 0 |
|
| HPIV | 2 (0.7) | 1 (0.2) | 0 | 0 | 0.445 |
| Others | 2 (0.7) | 6 (1.3) | 0 | 3 (1.1) | 0.370 |
PER, pediatric emergency room; GP, general practitioner; HRV, human rhinovirus; HPIV, human parainfluenza virus.
Others included: Mycoplasma pneumoniae, Bordetella parapertussis, enterovirus, metapneumovirus, RSV, influenza virus, and Bordetella pertussis. Significant p-values are highlighted in bold.
FIGURE 1Trend in the number of the main pathogens detected over time; data are represented as the number of positive subjects for each of the viruses considered: gray bar, total number of test; black, SARS-CoV-2; red, other coronaviruses; yellow, HRV; blue, adenovirus; green, HPIV. Data are represented starting from August 1, 2020 (week 31) until March 31, 2021 (week 13). HRV, human rhinovirus; HPIV, human parainfluenza virus.
Coinfections detected.
| Coinfections detected (total: 116/1,227, 9.5%) | |
| SARS-CoV-2/other coronaviruses | 1 (0.9) |
| SARS-CoV-2/HRV | 11 (9.5) |
| SARS-CoV-2/adenovirus | 0 |
| SARS-CoV-2/bocavirus | 3 (2.5) |
| HRV/other coronaviruses | 19 (16.4) |
| HRV/adenovirus | 49 (42.2) |
| HRV/bocavirus | 14 (12.1) |
| Adenovirus/other coronaviruses | 9 (7.8) |
| Adenovirus/bocavirus | 0 |
| Bocavirus/other coronaviruses | 3 (2.5) |
| SARS-CoV-2/HRV/adenovirus | 1 (0.9) |
| SARS-CoV-2/adenovirus/bocavirus | 1 (0.9) |
| HRV/adenovirus/bocavirus | 2 (1.7) |
| HRV/adenovirus/enterovirus | 1 (0.9) |
| HRV/other coronaviruses/bocavirus | 2 (1.7) |
HRV, human rhinovirus.
Bivariate logistic model for the risk of coinfections by age group.
| Coinfections | OR | 95% CI | |
|
| |||
| <2 (ref.) | – | – | – |
| 2–5 | 1.12 | (0.73; 1.73) | 0.592 |
| 6–9 | 0.28 | (0.13; 0.62) |
|
| 10–17 | 0.13 | (0.05; 0.34) |
|
Significant p-values are highlighted in bold.
Multinomial logistic model for the positivity to one of the detected viruses.
| Ref. Negative swab | SARS-CoV-2 | Other coronaviruses | HRV | Adenovirus | Bocavirus | ||||||||||
|
|
|
|
|
| |||||||||||
| RRR | 95% CI | RRR | 95% CI | RRR | 95% CI | RRR | 95% CI | RRR | 95% CI | ||||||
| Age | 0.98 | (0.90; 1.06) | 0.539 | 0.85 | (0.79; 0.91) |
| 0.95 | (0.92; 0.99) |
| 0.78 | (0.71; 0.86) |
| 0.88 | (0.75; 1.03) | 0.112 |
| Ward of provenience | |||||||||||||||
| GP (ref.) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| PER | 1.76 | (0.75; 4.11) | 0.193 | 3.13 | (1.65; 5.93) |
| 0.40 | (0.29; 0.55) |
| 2.14 | (1.10; 4.18) |
| 2.81 | (0.57; 13.8) | 0.201 |
| Contact with positive person to SARS-CoV-2 | 17.25 | (4.90; 60.71) |
| – | – | – | 1.22 | (0.33; 4.44) | 0.768 | 0.82 | (0.09; 7.72) | 0.864 | – | – | – |
| Fever | 2.88 | (1.08; 7.69) |
| 1.18 | (0.69; 2.03) | 0.546 | 0.65 | (0.47; 0.90) |
| 6.44 | (2.56; 16.20) |
| 0.44 | (0.12; 1.67) | 0.228 |
| Pharyngodynia | 0.99 | (0.28; 3.53) | 0.991 | 4.94 | (2.60; 9.38) |
| 1.38 | (0.87; 2.18) | 0.173 | 0.90 | (0.30; 2.72) | 0.852 | – | – | – |
| Cough | 1.13 | (0.44; 2.86) | 0.804 | 3.13 | (1.76; 5.59) |
| 1.79 | (1.27; 2.54) |
| 0.79 | (0.35; 1.75) | 0.554 | 1.87 | (0.46; 7.59) | 0.379 |
| Rhinitis | 1.60 | (0.65; 3.91) | 0.308 | 0.71 | (0.37; 3.97) | 0.317 | 1.53 | (1.08; 2.19) |
| 1.80 | (0.95; 3.42) |
| 0.56 | (0.11; 2.91) | 0.488 |
| Headache | 0.36 | (0.04; 3.11) | 0.354 | 0.37 | (0.05; 2.93) | 0.347 | 0.48 | (0.24; 0.97) |
| 0.56 | (0.06; 4.91) | 0.603 | – | – | – |
| Abdominal pain | 2.98 | (0.75; 11.91) | 0.122 | 1.23 | (0.38; 3.97) | 0.734 | 0.43 | (0.18; 1.00) |
| 2.67 | (0.66; 10.71) | 0.167 | 1.48 | (0.14; 15.71) | 0.745 |
| Nausea/vomiting | 0.44 | (0.06; 3.48) | 0.435 | 1.60 | (0.70; 3.66) | 0.269 | 0.75 | (0.42; 1.37) | 0.353 | 1.27 | (0.40; 4.01) | 0.687 | 1.07 | (0.18; 6.31) | 0.939 |
| Diarrhea | 0.69 | (0.14; 3.28) | 0.636 | 2.01 | (0.92; 4.36) |
| 0.54 | (0.28; 1.03) |
| 1.46 | (0.58; 3.69) | 0.423 | 1.53 | (0.29; 8.08) | 0.614 |
PER, pediatric emergency room; GP, general practitioner; HRV, human rhinovirus. Significant p-values are highlighted in bold.